Zacks Investment Research upgraded shares of Aytu BioScience (NASDAQ:AYTU) from a sell rating to a hold rating in a report issued on Wednesday morning, Zacks.com reports.

According to Zacks, “Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company’s marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Aytu BioScience, Inc. is based in Englewood, Colorado. “

Separately, HC Wainwright reiterated a buy rating and issued a $3.00 price objective on shares of Aytu BioScience in a research report on Thursday, August 6th.

Aytu BioScience stock opened at $0.95 on Wednesday. The company has a quick ratio of 2.51, a current ratio of 3.04 and a debt-to-equity ratio of 0.12. Aytu BioScience has a one year low of $0.34 and a one year high of $2.99. The business has a fifty day moving average price of $1.04 and a 200-day moving average price of $1.29.

Aytu BioScience (NASDAQ:AYTU) last issued its quarterly earnings data on Tuesday, November 17th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.02. Aytu BioScience had a negative return on equity of 25.20% and a negative net margin of 32.73%. On average, research analysts predict that Aytu BioScience will post -0.18 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AYTU. LPL Financial LLC purchased a new position in shares of Aytu BioScience in the third quarter worth about $29,000. Global Strategic Investment Solutions LLC bought a new stake in shares of Aytu BioScience in the second quarter worth about $31,000. Creative Planning bought a new stake in shares of Aytu BioScience in the second quarter worth about $32,000. HighTower Advisors LLC grew its stake in shares of Aytu BioScience by 52.0% in the second quarter. HighTower Advisors LLC now owns 24,849 shares of the company’s stock worth $35,000 after purchasing an additional 8,500 shares during the last quarter. Finally, UBS Group AG grew its stake in shares of Aytu BioScience by 437.3% in the second quarter. UBS Group AG now owns 25,960 shares of the company’s stock worth $36,000 after purchasing an additional 21,128 shares during the last quarter. Institutional investors and hedge funds own 8.30% of the company’s stock.

Aytu BioScience Company Profile

Aytu BioScience, Inc, a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension.

Further Reading: Stochastic Momentum Index (SMI)

Get a free copy of the Zacks research report on Aytu BioScience (AYTU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aytu BioScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioScience and related companies with MarketBeat.com's FREE daily email newsletter.